# A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

> **NCT06379789** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 130 (estimated)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** REGV131
- **DRUG:** LNP1265

## Key facts

- **NCT ID:** NCT06379789
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-11
- **Primary completion:** 2034-08-14
- **Final completion:** 2047-08-14
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06379789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06379789, "A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06379789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*